{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:31:35Z","timestamp":1787920295269,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10067-023-06579-8","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T14:06:14Z","timestamp":1679493974000},"page":"1959-1963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6047-6196","authenticated-orcid":false,"given":"Kensuke","family":"Irino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1031-1980","authenticated-orcid":false,"given":"Fumiaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-8066","authenticated-orcid":false,"given":"Shota","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6578-9688","authenticated-orcid":false,"given":"Takuya","family":"Sawabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"6579_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/asheducation-2015.1.177","volume":"2015","author":"CE Allen","year":"2015","unstructured":"Allen CE, McClain KL (2015) Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematol Am Soc Hematol Educ Program 2015:177\u2013182. https:\/\/doi.org\/10.1182\/asheducation-2015.1.177","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"6579_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"J-I Henter","year":"2007","unstructured":"Henter J-I, Horne A, Aric\u00f3 M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124\u2013131. https:\/\/doi.org\/10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"6579_CR3","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133:2465\u20132477. https:\/\/doi.org\/10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"6579_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjh.13837","volume":"172","author":"AM Schram","year":"2016","unstructured":"Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K et al (2016) Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol 172:412\u2013419. https:\/\/doi.org\/10.1111\/bjh.13837","journal-title":"Br J Haematol"},{"key":"6579_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.amjmed.2014.04.034","volume":"127","author":"S Rivi\u00e8re","year":"2014","unstructured":"Rivi\u00e8re S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, Fardet L (2014) Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med 127:1118\u20131125. https:\/\/doi.org\/10.1016\/j.amjmed.2014.04.034","journal-title":"Am J Med"},{"key":"6579_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","volume":"894","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP (2014) Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 894:484\u2013492. https:\/\/doi.org\/10.1016\/j.mayocp.2013.12.012","journal-title":"Mayo Clin Proc"},{"key":"6579_CR7","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan C, Nichols KE, Albeituni S (2021) Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol 12:614704. https:\/\/doi.org\/10.3389\/fimmu.2021.614704","journal-title":"Front Immunol"},{"key":"6579_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","volume":"12","author":"JH Sin","year":"2019","unstructured":"Sin JH, Zangardi ML (2019) Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther 12:166\u2013170. https:\/\/doi.org\/10.1016\/j.hemonc.2017.07.002","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"6579_CR9","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill SA, Alsawah F, Bockenstedt P, Campagnaro E, Devata S et al (2019) Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol 6:e630\u2013e637. https:\/\/doi.org\/10.1016\/S2352-3026(19)30156-5","journal-title":"Lancet Haematol"},{"key":"6579_CR10","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","volume":"105","author":"J Wang","year":"2020","unstructured":"Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z et al (2020) Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica 105:e210\u2013e212. https:\/\/doi.org\/10.3324\/haematol.2019.222471","journal-title":"Haematologica"},{"key":"6579_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/ejh.13593","volume":"106","author":"S Hansen","year":"2021","unstructured":"Hansen S, Alduaij W, Biggs CM, Belga S, Luecke K, Merkeley H et al (2021) Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series. Eur J Haematol 106:654\u2013661. https:\/\/doi.org\/10.1111\/ejh.13593","journal-title":"Eur J Haematol"},{"key":"6579_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383:1503\u20131516. https:\/\/doi.org\/10.1016\/S0140-6736(13)61048-X","journal-title":"Lancet"},{"key":"6579_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2141.1994.tb04905.x","volume":"87","author":"K Akashi","year":"1994","unstructured":"Akashi K, Hayashi S, Gondo H, Mizuno S, Harada M, Tamura K et al (1994) Involvement of interferon-\u03b3 and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 87:243\u2013250. https:\/\/doi.org\/10.1111\/j.1365-2141.1994.tb04905.x","journal-title":"Br J Haematol"},{"key":"6579_CR14","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1182\/blood.V89.11.4100","volume":"89","author":"Y Osugi","year":"1997","unstructured":"Osugi Y, Hara J, Tagawa S, Takai K (1997) Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89:4100\u20134103. https:\/\/doi.org\/10.1182\/blood.V89.11.4100","journal-title":"Blood"},{"key":"6579_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-2141.1999.01504.x","volume":"106","author":"H Takada","year":"1999","unstructured":"Takada H, Ohga S, Mizuno Y, Suminoe A, Matsuzaki A, Ihara K et al (1999) Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity. Br J Haematol 106:182\u2013189. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01504.x","journal-title":"Br J Haematol"},{"key":"6579_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2016.05.022","volume":"85","author":"SL Yang","year":"2016","unstructured":"Yang SL, Xu XJ, Tang YM, Song H, Xu WQ, Zhao FY, Shen DY (2016) Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine 85:14\u201317. https:\/\/doi.org\/10.1016\/j.cyto.2016.05.022","journal-title":"Cytokine"},{"key":"6579_CR17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jpeds.2013.06.053","volume":"163","author":"S Chandrakasan","year":"2013","unstructured":"Chandrakasan S, Filipovich AH (2013) Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr 163:1253\u20131259. https:\/\/doi.org\/10.1016\/j.jpeds.2013.06.053","journal-title":"J Pediatr"},{"key":"6579_CR18","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","volume":"127","author":"R Das","year":"2016","unstructured":"Das R, Guan P, Sprague L, Verbist K, Tedrick P, An QA et al (2016) Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 127:1666\u20131675. https:\/\/doi.org\/10.1182\/blood-2015-12-684399","journal-title":"Blood"},{"key":"6579_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/blood.2019000761","volume":"134","author":"S Albeituni","year":"2019","unstructured":"Albeituni S, Verbist KC, Tedrick PE, Tillman H, Picarsic J, Bassett R et al (2019) Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood 134:147\u2013159. https:\/\/doi.org\/10.1182\/blood.2019000761","journal-title":"Blood"},{"key":"6579_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16:843\u2013862. https:\/\/doi.org\/10.1038\/nrd.2017.201","journal-title":"Nat Rev Drug Discov"},{"key":"6579_CR21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/ph14080738","volume":"14","author":"M Gatti","year":"2021","unstructured":"Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C (2021) Janus kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues. Pharmaceuticals (Basel) 14:738. https:\/\/doi.org\/10.3390\/ph14080738","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06579-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T09:26:47Z","timestamp":1686734807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06579-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6579"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06579-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"22 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for this case report was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}